SSY GROUP (02005) released its interim results, with profit attributable to shareholders of HK$320 million, an increase of 12.99% year-on-year.

SSY GROUP (02005) announced its interim results for 2026, achieving revenue of HKD 2.361 billion, a year-on-year increase of 9.94%; profit attributable to equity holders of the company was HKD 320 million, up 12.99% year-on-year; basic earnings per share were HKD 0.1107, and an interim dividend of HKD 0.055 per share is proposed. The group actively participates in national and local centralized procurement, fully promoting the market entry and rapid scaling of new and high-quality products, steadily expanding its market coverage. In the first half of the year, it participated in 407 local procurement projects at the municipal level and above. As of now, the cumulative number of selected product specifications for centralized procurement has reached 269. In the continuation of national procurement agreements, 55 product specifications, including metronidazole tablets, dexmedetomidine hydrochloride injection, and inhalation solution of ipratropium bromide, won bids. In the centralized procurement of pharmaceuticals in Shandong Province, five product specifications won bids with a significant advantage, further expanding the regional market influence. Meanwhile, the group efficiently managed new product market access, with over 20 provinces approving 8 products and over 15 provinces approving another 6 products, with the market access coverage rate of products continuously improving, laying a solid foundation for future performance growth. In the IV infusion business, the group actively seizes market opportunities and increases its market development efforts, with steady results emerging. In the first half of the year, the production and sales volume of IV infusions achieved growth against the trend, with sales reaching 868 million bottles (bags), an increase of 21.4% year-on-year; and revenue of HKD 1.487 billion, up 24.0% year-on-year. While strengthening the connection between production and sales, accelerating digital transformation, and focusing on cost reduction and efficiency improvement, the group positively builds a product matrix oriented towards terminal market value, continuously optimizing market layout and segmentation strategies, and strives to enhance the sales proportion of therapeutic infusions, large-sized products, and peritoneal dialysis solutions, thereby solidifying the market foundation of the IV infusion business, with an overall stable supply and demand pattern. Through intensified market development efforts, the sales of mannitol injection reached 19.75 million bottles (bags), a year-on-year increase of 19%; sales of moxifloxacin hydrochloride sodium chloride injection reached 6.17 million bags, up 23% year-on-year; and sales of peritoneal dialysis solutions reached 5.31 million bags, a remarkable increase of 121%; sales of levofloxacin sodium chloride injection reached 5.24 million bags, up 17% year-on-year. In the water injection business, during the first half of the year, ampoule water injections reached sales of 178.81 million units, a year-on-year increase of 0.4%; revenue was HKD 163 million, up 3.5% year-on-year. Although the sales of water injections did not meet expectations, the selected products from the national procurement maintained a significant advantage. Among them, lidocaine hydrochloride injection achieved sales of 2.57 million units, up 99% year-on-year; ornidazole injection achieved sales of 2.39 million units, up 64% year-on-year; betamethasone sodium phosphate injection achieved sales of 13.34 million units, up 19% year-on-year; and inhalation solution of ipratropium bromide achieved sales of 12.44 million units, up 28% year-on-year. In the oral dosage form business, the group continues to enrich its inventory of generic drugs subject to consistency evaluation and expand market share. In the first half of the year, due to the overall low prevalence level of respiratory tract infections, there was some seasonal antiviral medication stock in the distribution channels, reflecting cyclical fluctuations in the industry. Oral formulations achieved revenue of HKD 165 million, a year-on-year decrease of 44%, but the sector's performance showed structural differentiation, with some advantageous varieties maintaining stable market competitiveness, recording steady growth in sales, and the overall fundamentals of oral chemical preparations remaining solid. Among them, rosuvastatin calcium tablets achieved sales of 171.01 million tablets, up 14% year-on-year; valsartan and amlodipine tablets (I) achieved sales of 61.11 million tablets, up 69% year-on-year; and nifedipine sustained-release tablets (II) achieved sales of 27.32 million tablets, up 86% year-on-year. In the active pharmaceutical ingredient (API) business, facing adverse factors such as weak market demand and changes in domestic and international tariff policies, the group has strengthened cooperation with large domestic and international clients and high-end customers through measures such as increasing overseas product registration and international certification efforts, as well as deepening market potential. In the first half of the year, API revenue reached HKD 395 million, a year-on-year increase of 9.4%.